CHARLESTON, S.C. (WCSC) — An ongoing trial at the Medical University of South Carolina is looking for a breakthrough for patients dealing with heart failure. The condition is called heart failure with ...
Hosted on MSN
Insmed halts CRSsNP program after Phase 2b failure
The latest announcement is out from Insmed ( (INSM)). On December 17, 2025, Insmed announced the Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) did not ...
argenx SE retains a Hold rating due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART. Recent termination of TED and lupus nephritis programs narrows ...
On November 17, 2025, Health Canada proposed Phase II amendments to the Medical Devices Regulations (MDR). The first phase of amendments came into force on December 14, 2024 and relate to recalls, ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Impulse Dynamics said Wednesday that it has raised $158 ...
An FDA advisory panel declined to endorse the Ventura interatrial shunt system, a heart failure device developed by V-Wave, a Johnson & Johnson company, according to a Dec. 5 TCTMD report. Panel ...
The UK's National Cyber Security Center (NCSC) announced the testing phase of a new service called Proactive Notifications, designed to inform organizations in the country of vulnerabilities present ...
BMS and AstraZeneca said the IDMC does not believe the ACS trial will meet its primary endpoint. Image credit: Piyaset / Shutterstock.com. Bristol Myers Squibb (BMS) and AstraZeneca have decided to ...
TUCSON, Ariz. (KVOA) - Carondelet St. Mary’s Hospital has achieved a milestone by completing its first procedure to implant the Barostim™ Baroreflex Activation Therapy device. This innovative heart ...
TUCSON, Ariz. (KVOA) - Carondelet St. Mary's Hospital has successfully completed its first implantation of the Barostim™ Baroreflex Activation Therapy device, marking a significant advancement in the ...
The phase 2 trial showed that coramitug, an antibody targeting misfolded transthyretin in ATTR-CM, was well tolerated. A dose of 60 mg/kg resulted in a statistically significant reduction in NT-proBNP ...
Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results